This Is Novavax's Biggest Weakness Right Now -- and Here's How the Company May Overcome It

Novavax (NASDAQ: NVAX) investors have been eagerly awaiting one thing -- for the company to request authorization to sell its coronavirus vaccine candidate. Earlier this year, Novavax indicated that would happen in the second quarter. So, the move seemed imminent.

And then came the disappointment. During the first-quarter earnings report this week, Novavax said it needed more time. The company now expects to file for Emergency Use Authorization in the third quarter. As a result, the shares sank nearly 14% in one trading session. This news leads us to Novavax's biggest problem right now. Let's take a close look at that problem and how the biotech company may succeed in spite of it.

Image source: Getty Images.

Continue reading

Source Fool.com